PDG23 Comparing Average Time to Listing and Drug Coverage Rates between Provinces in Canada

Abstract

Following Health Technology Assessment (HTA) reviews by the Canadian Agency for Drugs and Technologies in Health (CADTH), the decision to publicly fund drugs remains to respective public drug plans (federal, provincial, and territorial). The objective of this analysis was to evaluate the varying times between CADTH Common Drug Review (CDR) recommendations and listings among Canadian provinces (except Quebec), along with the differences between proportions of drugs covered per province.